1. 1830 Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques. (September 2015) Authors: Heil, J.; Kümmel, S.; Schaefgen, B.; Paepke, S.; Thomssen, C.; Rauch, G.; Ataseven, B.; Große, R.; Dreesmann, V.; Kühn, T.; Loibl, S.; Blohmer, J.U.; Minckwitz, G.V. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S275 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1956 Safety and tolerability of subcutaneous trastuzumab for HER2-positive early breast cancer in patients with lower body weight and in Asian patients: SafeHer Phase III study subgroup analyses. (September 2015) Authors: Jung, K.H.; Ataseven, B.; Verrill, M.; De Laurentiis, M.; Azim, H.A.; Pivot, X.; Al-Sakaff, N.; Lauer, S.; Shing, M.; Gligorov, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S318 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 2743 The revised 2014 FIGO staging system for epithelial ovarian cancer: Is a subclassification of stage IV justified?. (September 2015) Authors: Ataseven, B.; Harter, P.; Heitz, F.; Traut, A.; Prader, S.; DuBois, A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S544 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 2744 Stage IV ovarian cancer: Prognosis of patients with exclusively abdominal wall metastasis. (September 2015) Authors: Ataseven, B.; Harter, P.; Heitz, F.; Traut, A.; Prader, S.; Bois, A. Du Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S544 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial. (April 2021) Authors: Gligorov, J.; Pivot, X.; Ataseven, B.; De Laurentiis, M.; Llombart, A.; Jung, K.H.; Manikhas, A.; Azim, H.A.; Alexandrou, A.; Gupta, K.; Herraez-Baranda, L.; Tosti, N.; Restuccia, E. Journal: Breast Issue: Volume 56(2021)Supplement 1 Page Start: S21 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P103 Subcutaneous trastuzumab plus chemotherapy for early breast cancer: interim safety from SafeHer. (March 2015) Authors: Gligorov, J.; De Laurentiis, M.; Verrill, M.; Jung, K.H.; Azim, H.A.; Ataseven, B.; Al-Sakaff, N.; Heinzmann, D.; Shing, M.; Pivot, X. Journal: Breast Issue: Volume 24(2015)Supplement 1 Page Start: S60 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. (September 2017) Authors: Gligorov, J.; Ataseven, B.; Verrill, M.; De Laurentiis, M.; Jung, K.H.; Azim, H.A.; Al-Sakaff, N.; Lauer, S.; Shing, M.; Pivot, X. Journal: European journal of cancer Issue: Volume 82(2017) Page Start: 237 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗